What it is
RFantibody uses generative structural modelling for epitope-conditioned de novo antibody design and connects structural generation with sequence design and validation.
Evidence trail
BioAtlas keeps the path from source to decision visible. A connection records provenance; it does not imply that evidence is sufficient for every context.
Model passport
How RFantibody represents biology
Category is navigation. These fields describe the model-specific computational transformation and deliberately override broad category defaults.
Biological scale
Modalities & tasks
Registry, claims and frontier intelligence
RFantibody
1 version record · latest curated year 2025. Model-family identity remains separate from capability and access changes.
Explore version lineage →1 normalized claim
Antibody sequence modelling · Experimental antibody design
Open claim intelligence →0 connected frontiers
No frontier-research record currently connects to this model.
Inspect research horizon →Inputs and outputs
Inputs
Target epitope / antigen structureOutputs
Antibody candidatesPredicted complexesScientific and technical profile
Scientific principles
Technology
Scientific lineage
These are transparent concept matches—not claims that one scientist alone caused this model. Each connection is based on the model’s recorded domain, scientific principles, technical terms or an explicit lineage link.
Hybridoma production of monoclonal antibodies
Georges J. F. Köhler & César MilsteinTherapeutic antibodies, diagnostic antibodies and antibody discovery platforms became scalable and reproducible.
Somatic gene rearrangement generates antibody diversity
Susumu TonegawaAntibody language models and repertoire design operate on the sequence space created by V(D)J recombination and somatic diversification.
Computational protein structure prediction and de novo design
David BakerModern binder design, inverse folding and diffusion-based protein generation build on this computational-design lineage.
Denoising diffusion generative models
Jascha Sohl-Dickstein, Jonathan Ho and collaboratorsModern protein-backbone, molecular-pose and biomolecular-complex generators use diffusion to sample valid three-dimensional structures and designs.
Selective toxicity and the ‘magic bullet’
Paul EhrlichTarget selectivity, therapeutic index and mechanism-based screening remain central goals of drug discovery.
Atomic structures of biologically important molecules by X-ray crystallography
Dorothy Crowfoot HodgkinStructure-based drug design depends on the experimental structural tradition she helped establish.
Evaluation evidence
Task-specific evidence only; not comparable as a universal leaderboard score.
Experimental antibody design
RFantibody · Split details not yet normalizedA structured benchmark claim is recorded; consult the linked source for numeric values and protocol details.
Claim caveats
- Protocol, split and implementation details must match before comparing this claim with another result.
Known limitations
- Performance depends on the evaluation dataset and operating conditions.
- Task-specific benchmark results should not be compared across unlike domains.
- Outputs require task-specific scientific and experimental validation.
Milestones
Experimentally evaluated de novo antibody designs have been reported.